Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ADPT 
Adaptive Biotechnologies Corp (ADPT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: ADPT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11.86
1 Year Target Price $11.86
| 3 | Strong Buy |
| 4 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -41.07% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.86B USD | Price to earnings Ratio - | 1Y Target Price 11.86 |
Price to earnings Ratio - | 1Y Target Price 11.86 | ||
Volume (30-day avg) 8 | Beta 1.79 | 52 Weeks Range 3.85 - 12.43 | Updated Date 07/11/2025 |
52 Weeks Range 3.85 - 12.43 | Updated Date 07/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.95 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -74.84% | Operating Margin (TTM) -56.45% |
Management Effectiveness
Return on Assets (TTM) -15.05% | Return on Equity (TTM) -61.03% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1705842493 | Price to Sales(TTM) 9.8 |
Enterprise Value 1705842493 | Price to Sales(TTM) 9.8 | ||
Enterprise Value to Revenue 9 | Enterprise Value to EBITDA -1 | Shares Outstanding 151916992 | Shares Floating 103894327 |
Shares Outstanding 151916992 | Shares Floating 103894327 | ||
Percent Insiders 2.35 | Percent Institutions 98.36 |
Upturn AI SWOT
Adaptive Biotechnologies Corp
Company Overview
History and Background
Adaptive Biotechnologies was founded in 2009. It focuses on leveraging the adaptive immune system to develop diagnostics and therapeutics. Initially focused on research, it has expanded into commercial applications.
Core Business Areas
- Therapeutics: Developing novel T-cell receptor (TCR)-based therapeutics for cancer and other diseases.
- Minimal Residual Disease (MRD) Diagnostics: Providing clonoSEQ assays for detecting and monitoring minimal residual disease in blood cancers.
- Drug Discovery: Using its immune medicine platform to discover novel drug targets and develop new therapies.
Leadership and Structure
The leadership team includes CEO and various VPs heading different departments. The company is structured with distinct divisions for diagnostics, therapeutics, and research.
Top Products and Market Share
Key Offerings
- clonoSEQ: clonoSEQ is a test to detect and monitor minimal residual disease (MRD) in patients with multiple myeloma, B-cell acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). Competitors include Invitae (NVTA) and Labcorp (LH).
- T-Detect: T-Detect is a test to detect prior or present T cell immune response to certain pathogens and diseases such as COVID-19. No specific market share data is available. Competitors include Quanterix (QTRX) and PerkinElmer (PKI).
Market Dynamics
Industry Overview
The diagnostics and therapeutics market is experiencing growth, driven by technological advancements and increasing demand for personalized medicine.
Positioning
Adaptive Biotechnologies is positioned as an innovative company leveraging the adaptive immune system for diagnostics and therapeutics, with a focus on personalized medicine. Its competitive advantages include a robust technology platform and strategic partnerships.
Total Addressable Market (TAM)
TAM estimated in billions of dollars. Adaptive Biotechnologies is positioned to capture a portion of the MRD testing and immune-driven therapy markets.
Upturn SWOT Analysis
Strengths
- Proprietary immune medicine platform
- Strategic partnerships with leading pharmaceutical companies
- Established clonoSEQ diagnostic product
- Strong intellectual property portfolio
Weaknesses
- Limited profitability
- Dependence on partnerships for revenue
- High research and development costs
- Limited commercial infrastructure
Opportunities
- Expansion into new therapeutic areas
- Increased adoption of MRD testing
- Development of new diagnostic products
- Leveraging data insights for drug discovery
Threats
- Competition from established diagnostic companies
- Regulatory hurdles for new products
- Technological obsolescence
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- INVITAE CORP (NVTA)
- GUARDANT HEALTH INC (GH)
- NATERA INC (NTRA)
Competitive Landscape
Adaptive Biotechnologies faces competition from larger, more established diagnostic companies. Its advantage lies in its unique technology platform and focus on personalized medicine.
Major Acquisitions
No recent major acquisitions
- Year: 2023
- Acquisition Price (USD millions): 0
- Strategic Rationale: N/A
Growth Trajectory and Initiatives
Historical Growth: Historical growth can be assessed using past revenue and profit figures (available in past financial reports).
Future Projections: Future growth projections can be obtained from analyst reports and company guidance.
Recent Initiatives: Recent initiatives include partnerships for therapeutic development and expansion of diagnostic testing services.
Summary
Adaptive Biotechnologies is an innovative company pioneering immune-driven diagnostics and therapeutics. While possessing a strong technology platform and strategic partnerships, its profitability remains a concern. Growth opportunities exist in expanding its product line and therapeutic applications. It must navigate competition and regulatory hurdles to achieve sustainable success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Adaptive Biotechnologies Corp
Exchange NASDAQ | Headquaters Seattle, WA, United States | ||
IPO Launch date 2019-06-27 | Co-Founder, CEO & Chairman Mr. Chad M. Robins M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 619 | Website https://www.adaptivebiotech.com |
Full time employees 619 | Website https://www.adaptivebiotech.com | ||
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. It has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.